BenchSci is an AI-powered platform that aids scientists in experiment decision-making and accelerates drug discovery by providing an unmatched understanding of disease biology.

BenchSci

Biotechgate provides information and solutions for the life sciences industry, including databases for clinical trials and investor connections. The service offers access to business development and licensing information self-described as comprehensive.

Biotechgate

Collaborative Drug Discovery Inc. provides scientific data management and electronic laboratory notebook software through its product CDD Vault, which aims to organize and analyze research data.

Collaborative Drug Discovery Inc.

DVLP is building a new infrastructure for drug development by digitizing drug assets, financing, and development workflows to accelerate the process of turning molecules into medicines.

DVLP

BenchSci’s vision is to exponentially increase the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence.

Backed by F-Prime, Gradient Ventures (Google’s AI fund), Inovia Capital, and TCV, our platform accelerates science at 16 of the top-20 pharmaceutical companies, and over 4,300 leading research centers worldwide.

We’re a remote-first company recognized for our impact and culture as a Deloitte Tech Fast 50TM, CIX Top 10 Growth, Great Place to Work®, and top-ranked organization on Glassdoor.

500 Startups Canada

Afore Capital

Radical Ventures

Gradient Ventures

Golden Ventures

Inovia Capital

F-Prime Capital

Northleaf Capital Partners

Real Ventures

Generation Investment Management

The greatest opportunity for AI and GenAI in drug discovery lies in unraveling the complexities of disease biology. 

At BenchSci, we are excited to accelerate our efforts as we work towards our mission to improve the speed and quality of R&D, helping deliver life-changing medicines to patients faster. Check out our latest blog post from BenchSci CEO & Co-Founder Liran Belenzon (he/him), where he explores: 

✔ The pivotal role of GenAI in pharma R&D
✔ How BenchSci’s ASCEND is shaping the future of drug discovery—the disease biology GenAI platform for pharma R&D
✔ The promising future of GenAI in revolutionizing drug discovery 

https://lnkd.in/gNBihdDV

#GenAI #artificialintelligencetechnology 

Earlier today, we shared with our team the difficult news that we are implementing company-wide workforce changes. This decision was not made lightly and resulted in BenchSci saying goodbye to a group of incredibly talented individuals. The decision is a result of shifts in the economic environment, operational efficiencies, and adaptation to technological advancements, specifically Generative AI.

We believe that Generative AI will continue to reshape preclinical R&D and have a substantial positive impact on our customers. As we look towards our future, these changes will allow us to further our investment in Generative AI and work toward making drug discovery more efficient and help bring new medicine to patients faster. 

We are extremely thankful to every BenchScier for their continued dedication and partnership and are fully committed to supporting them through this transition.  

Earlier today, Google Cloud unveiled its new MedLM technology, its latest medically tuned model. 

As an early adopter of LLMs and leader in Biomed AI R&D, BenchSci was among a select group of exclusive partners with early access to MedLM. Hear more about how we're integrating MedLM into our proprietary ASCEND technology to accelerate a best-in-class Biomarker solution from BenchSci Co-Founder and CEO, Liran Belenzon (he/him), who spoke with CNBC.

https://lnkd.in/dYm8My9N

“As a company that values continuous improvement of ourselves and our world, we consider the work and commitment to DEI to be our collective responsibility. Not only is it the right thing to do for our business, it's the right thing to do—period.” Liran Belenzon (he/him)

Today, Great Place to Work® Canada unveiled its 2023 Best Places to Work for Inclusion list, which highlights our ongoing dedication to building and fostering an inclusive environment at BenchSci. 

This recognition comes as a result of every single BenchScier. The work we’ve done and continue to do to create a fair and welcoming environment, is a testament to the dedication of BenchSciers across the entire company. 

Check out our latest blog post from BenchSci’s Diversity, Equity, and Inclusion Program Manager, Shelby Reaburn who spoke with (some of the many) BenchSciers who continue to shape and refine our culture every day including, Christopher Guest, Miya Badley, Wisam Zaghal, Jordan Newington, PhD, Wai Chung Hon, P.Eng., CSM, and Fernando José Suarez Saiz.

https://lnkd.in/gX_QaJpu

#Gptwcertified #Inclusive4All #Bestworkplaces #inclusion #diversity

A few weeks ago, BenchSciers, including members of our Black@BenchSci ERG, attended the largest tech conference for Black professionals, the BFUTR conference in Toronto. This year, we expanded our partnership to have a booth, which allowed us to engage with over 400 individuals, forging valuable connections and expanding our talent pipeline. 

Check out our latest blog post to hear more from Black@BenchSci's Community Manager, Amalia Ward, and BenchSci's Co-Founder and Chief Data Officer, Elvis Wianda.

#BFUTR2023 #BPTN #OBSIDI

https://lnkd.in/gskcQGFg

Metric
Company Name	BenchSci	Biotechgate	Collaborative Drug Discovery Inc.	DVLP
Symbol
MSH ID	COM:BENCHSCI	COM:BIOTECHGATE	COM:COLLABORATIVEDRUG	COM:DVLPMEDICINES
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Commercial & Professional Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare & Health Services	Life Sciences	Biotechnology	Pharmaceuticals
Country	CA	CH	US	US
Stage
Employee Count	393
Website	benchsci.com	biotechgate.com	collaborativedrug.com	dvlpmedicines.com
LinkedIn	benchsci	biotechgate		dvlpmedicines
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		2.80K
Web Traffic Growth		2.27
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:BENCHSCI

BenchSci

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue